80 related articles for article (PubMed ID: 24088604)
1. The development of the metabolic syndrome and insulin resistance after adjuvant treatment for breast cancer.
Guinan EM; Connolly EM; Healy LA; Carroll PA; Kennedy MJ; Hussey J
Cancer Nurs; 2014; 37(5):355-62. PubMed ID: 24088604
[TBL] [Abstract][Full Text] [Related]
2. The presentation of metabolic dysfunction and the relationship with energy output in breast cancer survivors: a cross-sectional study.
Guinan EM; Connolly EM; Kennedy MJ; Hussey J
Nutr J; 2013 Jul; 12():99. PubMed ID: 23855321
[TBL] [Abstract][Full Text] [Related]
3. Key metabolic parameters change significantly in early breast cancer survivors: an explorative PILOT study.
Fredslund SO; Gravholt CH; Laursen BE; Jensen AB
J Transl Med; 2019 Apr; 17(1):105. PubMed ID: 30935397
[TBL] [Abstract][Full Text] [Related]
4. Impact of traits of metabolic syndrome on β-cell function and insulin resistance in normal fasting, normal glucose tolerant subjects.
Cubeddu LX; Hoffmann IS
Metab Syndr Relat Disord; 2012 Oct; 10(5):344-50. PubMed ID: 22803772
[TBL] [Abstract][Full Text] [Related]
5. Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome.
Tzotzas T; Samara M; Constantinidis T; Tziomalos K; Krassas G
Angiology; 2007; 58(1):26-33. PubMed ID: 17351155
[TBL] [Abstract][Full Text] [Related]
6. Relationship between insulin resistance and some coagulation and fibrinolytic parameters in patients with metabolic syndrome.
Ragab A; Abousamra NK; Higazy A; Saleh O
Lab Hematol; 2008; 14(1):1-6. PubMed ID: 18403313
[TBL] [Abstract][Full Text] [Related]
7. High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome.
Goodwin PJ; Ennis M; Bahl M; Fantus IG; Pritchard KI; Trudeau ME; Koo J; Hood N
Breast Cancer Res Treat; 2009 Apr; 114(3):517-25. PubMed ID: 18437560
[TBL] [Abstract][Full Text] [Related]
8. Metabolic factors, anthropometric measures, diet, and physical activity in long-term breast cancer survivors: change from diagnosis and comparison to non-breast cancer controls.
Lohmann AE; Ennis M; Taylor SK; Goodwin PJ
Breast Cancer Res Treat; 2017 Jul; 164(2):451-460. PubMed ID: 28444534
[TBL] [Abstract][Full Text] [Related]
9. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis.
Reilly MP; Wolfe ML; Rhodes T; Girman C; Mehta N; Rader DJ
Circulation; 2004 Aug; 110(7):803-9. PubMed ID: 15289378
[TBL] [Abstract][Full Text] [Related]
10. The metabolic profile in active acromegaly is gender-specific.
Ciresi A; Amato MC; Pivonello R; Nazzari E; Grasso LF; Minuto F; Ferone D; Colao A; Giordano C
J Clin Endocrinol Metab; 2013 Jan; 98(1):E51-9. PubMed ID: 23162101
[TBL] [Abstract][Full Text] [Related]
11. Effect of combination exercise training on metabolic syndrome parameters in postmenopausal women with breast cancer.
Nuri R; Kordi MR; Moghaddasi M; Rahnama N; Damirchi A; Rahmani-Nia F; Emami H
J Cancer Res Ther; 2012; 8(2):238-42. PubMed ID: 22842368
[TBL] [Abstract][Full Text] [Related]
12. Visceral obesity, metabolic syndrome, insulin resistance and cancer.
Doyle SL; Donohoe CL; Lysaght J; Reynolds JV
Proc Nutr Soc; 2012 Feb; 71(1):181-9. PubMed ID: 22051112
[TBL] [Abstract][Full Text] [Related]
13. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome.
Güçlü F; Ozmen B; Hekimsoy Z; Kirmaz C
Biomed Pharmacother; 2004 Dec; 58(10):614-8. PubMed ID: 15589072
[TBL] [Abstract][Full Text] [Related]
14. The relationship of insulin resistance and metabolic syndrome with known breast cancer prognostic factors in postmenopausal breast cancer patients.
Can A; Alacacioglu A; Kucukzeybek Y; Erten C; Cokmert S; Demir L; Dirican A; Vedat Bayoglu I; Akyol M; Aslan F; Oktay Tarhan M
J BUON; 2013; 18(4):845-50. PubMed ID: 24344007
[TBL] [Abstract][Full Text] [Related]
15. Risk of metabolic syndrome in postmenopausal breast cancer survivors.
Buttros Dde A; Nahas EA; Vespoli Hde L; Uemura G; de Almeida Bda R; Nahas-Neto J
Menopause; 2013 Apr; 20(4):448-54. PubMed ID: 23149866
[TBL] [Abstract][Full Text] [Related]
16. Comparison of indices of insulin resistance with metabolic syndrome classifications to predict the development of impaired fasting glucose in overweight and obese subjects: a 3-year prospective study.
Shand BI; Scott RS; Lewis JG; Elder PA; Frampton CM
Int J Obes (Lond); 2009 Nov; 33(11):1274-9. PubMed ID: 19721448
[TBL] [Abstract][Full Text] [Related]
17. Obesity and physical inactivity are related to impaired physical health of breast cancer survivors.
Elme A; Utriainen M; Kellokumpu-Lehtinen P; Palva T; Luoto R; Nikander R; Huovinen R; Kautiainen H; Järvenpää S; Penttinen HM; Vehmanen L; Jääskeläinen AS; Ruohola J; Blomqvist C; Saarto T
Anticancer Res; 2013 Apr; 33(4):1595-602. PubMed ID: 23564803
[TBL] [Abstract][Full Text] [Related]
18. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome.
Lord J; Thomas R; Fox B; Acharya U; Wilkin T
BJOG; 2006 Oct; 113(10):1203-9. PubMed ID: 16753044
[TBL] [Abstract][Full Text] [Related]
19. Lifestyle modification increases circulating adiponectin concentrations but does not change vaspin concentrations.
Kim SM; Cho GJ; Yannakoulia M; Hwang TG; Kim IH; Park EK; Mantzoros CS
Metabolism; 2011 Sep; 60(9):1294-9. PubMed ID: 21489569
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive metabolic evaluation reveals impaired glucose metabolism and dyslipidemia in breast cancer patients early in the disease trajectory.
Bell KE; Di Sebastiano KM; Vance V; Hanning R; Mitchell A; Quadrilatero J; Russell C; Dubin JA; Bahl M; Califaretti N; Campbell C; Mourtzakis M
Clin Nutr; 2014 Jun; 33(3):550-7. PubMed ID: 24011971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
